



<b>Study Title:</b>	Treatment Trial to Test RAD001 Along With Standard Treatment for Newly Diagnosed Glioblastoma
<b>Scientific Title:</b>	RTOG 0913: Phase I/II Trial Of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed By Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma
<b>Department and/or Specialty:</b>	Regional Cancer Center - Brain
<b>Investigator:</b>	Wingate Clapper, MD
<b>Contact Information:</b>	Chanda Miller 262-928-5539

Everolimus may stop the growth of tumor cells by blocking some enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill tumor cells. Giving everolimus together with temozolomide and radiation therapy may kill more tumor cells.

This phase I/II trial is studying the side effects and best dose of everolimus when given together with temozolomide and radiation therapy and to see how well it works in treating patients with newly diagnosed glioblastoma multiforme.



**PROHEALTH CARE**  
RESEARCH INSTITUTE